Objective To study CSF biomarkers of Alzheimer disease (AD) analyzed by fully automated Elecsys immunoassays compared to neuropathologic gold standards and to compare their …
SL Risacher, N Fandos, J Romero, I Sherriff… - Alzheimer's & Dementia …, 2019 - Elsevier
Introduction We investigated the relationship of plasma amyloid beta (Aβ) with cerebral deposition of Aβ and tau on positron emission tomography (PET). Methods Forty-four …
WW Li, YY Shen, DY Tian, XL Bu… - Journal of …, 2019 - content.iospress.com
Brain amyloid-(A) deposition is a hallmark to define Alzheimer's disease (AD). We investigated the positive rate of brain amyloid deposition assessed with 11C-Pittsburgh …
MY Chun, H Jang, HJ Kim, JP Kim… - Frontiers in Aging …, 2023 - frontiersin.org
Background Early detection of β-amyloid (Aβ) accumulation, a major biomarker for Alzheimer's disease (AD), has become important. As fluid biomarkers, the accuracy of …
M Bucci, K Chiotis, A Nordberg… - Molecular …, 2021 - nature.com
For early detection of Alzheimer's disease, it is important to find biomarkers with predictive value for disease progression and clinical manifestations, such as cognitive decline …
Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD) …
Introduction Plasma tau may be an accessible biomarker for Alzheimer's disease (AD), but the correlation between plasma and cerebrospinal fluid (CSF) tau and the value of …
Background Cerebrospinal fluid biomarker profiles characterized by decreased amyloid- beta peptide levels and increased total and phosphorylated tau levels at threonine 181 …
H Hampel, A Goernitz, K Buerger - Brain research bulletin, 2003 - Elsevier
Advances have been made to establish biological markers of Alzheimer's disease (AD). Measurement of total tau (t-tau) and beta-amyloid1–42 (Aβ1–42) in the cerebrospinal fluid …